Hidradenitis Suppurativa Patient Experience With Humira Treatment
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Hidradenitis suppurativa (HS) is a chronic relapsing condition with significant psychosocial
impact and morbidity, but that doesn't mean that patients will necessarily be adherent to
recommended treatments. Patients, especially those on chronic medication therapy, inevitably
miss doses. They use too little or too much therapy. They may take medications too soon or
too far apart. While adherence to injection treatments tend to be better than adherence to
topical or oral treatment, adherence to injections may still be poor.
Traditional methods for measuring medical adherence-including questionnaires, surveys, and
diaries- tend to be unreliable overestimate adherence. Chemical markers are problematic
because of the tendency for patients to use their medication right before visits, so called
"white coat compliance." Our research team has pioneered the use of electronic monitoring
devices which measure and record the date and time of medication events to assess adherence
in dermatology. The study team have demonstrated the feasibility of using such monitors to
measure adherence to adalimumab in patients with psoriasis. Although only a small study, it
documented a broad range of how patients use adalimumab and found that adherence was poor in
about half of the patients. While the impact of psoriasis on patients' lives is large,
adherence is still poor. How adherent patients with hidradenitis are to weekly adalimumab
treatment is not yet well characterized.